Exicure Virtual KOL Event 2020
Virtual,
September 16, 2020
Exicure to discuss the preliminary Phase 1b safety and efficacy data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.Principal Investigators Dr. Steven J. O’Day and Dr. Shailender Bhatia will join Exicure’s leadership team in discussing clinical progress to date.
 |
Steven J. O’Day, MD, is the Executive Director of the John Wayne Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research. He is the Professor of Medical Oncology, Director of Immuno-Oncology, and Director of Clinical Research at the John Wayne Cancer Institute at Providence Saint John’s Health Center. | |
 |
Shailender Bhatia, MD, is an Associate Professor at the University of Washington School of Medicine and an Assistant Professor of the Clinical Research Division at the Fred Hutchinson Cancer Research Center. |
